The products reported missing include insulin formulations marketed as Ryzodeg FlexTouch and Fiasp (Penfill and FlexTouch), ...

NEW YORK — (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

A report on August 20, 2025 shows that Representative Marjorie Taylor Greene from Georgia purchase stock in Novo Nordisk NVO +10.2% Get Free Report , valued between $15,001 and $50,000. According to ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

The health sector faces a range of global challenges and developments, including Indian tax proposals, trade impacts on Brazilian chicken exports, and activist investment in Gerresheimer. Other key ...

The delays, first revealed in Regeron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...